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Objective. To evaluate the eﬃcacy of selective submandibular neck dissection (SMND) in patients with oral squamous cell
carcinoma (OSCC) with or without nodal metastasis. Patients. From a total of 384 patients with untreated OSCC who underwent
radical excision, we identiﬁed 229 with clinically N0 necks and 68 with clinically N1 necks in level I. Main Outcome Measures.T h e
Kaplan-Meier 5-year regional control and 5-year disease speciﬁc survival (DSS) were compared for SMND, radical neck dissection
(RND), and modiﬁed radical neck dissection (MRND). Results. In clinically node-negative necks, the regional control rates were
85.2% with SMND and 83.3% with MRND (P = 0.89), and 5-year DSS rates were 86.5% and 87.0%, respectively, (P = 0.94). In
clinically N1 necks, the regional control rates were 81.3% with SMND and 83.0% with RND (P = 0.72), and the DSS rates were
81.3% and 80.0%, respectively, (P = 0.94). Type of neck dissection was not signiﬁcantly associated with regional control or DSS
on either univariate or multivariate analysis using Cox’s proportional hazard model. Conclusions.S M N Dc a nb ee ﬀectively applied
in elective and therapeutic management to patients with OSCC that are clinically assessed as N0 or N1 to level I of the neck.
1.Introduction
Clinical decisions regarding neck dissection in the treatment
of oral squamous cell carcinoma (OSCC) should be based
not only on the potential completeness of the resection but
also on postoperative functional and cosmetic morbidity. In
recent years, selective neck dissection in patients with SCC
of the head and neck has been evaluated in terms of patient
quality of life, which can be signiﬁcantly compromised
following extensive dissection. However, to our knowledge,
little information has been published on determining the
appropriateness of selective neck dissection and adequate
dissection levels, especially in patients with SCC of the oral
cavity.
Surgical management of neck lymph nodes was classi-
cally controlled by radical neck dissection (RND), which
resects all of the neck lymph nodes (levels I–V, according to
the neck dissection classiﬁcation of the American Academy
of Otolaryngology Head and Neck Surgery [1]). Elective
management remains controversial in patients with OSCC
who have no clinical evidence of node involvement in the
neck. Several studies have asserted the need for elective neck
dissection because of the high incidence of occult metastases
fromOSCC,eveninitsearlystages[2].Modiﬁedradicalneck
dissection (MRND) is an alternative procedure that avoids
dysfunction of the neck region by preserving the accessory
nerve, internal jugular vein, and sternocleidomastoid muscle
in RND. Supraomohyoid neck dissection (SOHND), a type
of selective neck dissection, has gradually become the usual
procedure in elective situations [3], with the understanding
that OSCC carries a signiﬁcant risk of metastasizing to
cervical lymph nodes in neck levels I, II, and III [4].
Meanwhile, another report recommends a “watchful policy”
based on the observation that regional control and overall2 Journal of Oncology
survival were not signiﬁcantly diﬀerent with elective neck
dissection versus observation [5]. The conceptual basis for
this approach is that lymphatic structures may be considered
a defense mechanism against metastasis, so negative nodes
should be preserved. Accordingly, we do not performelective
neck dissections that would compromise a patient’s quality
of life. However, in cases in which the primary tumor
invades deep into the tongue or ﬂoor of the mouth, level
I lymph nodes should be resected as a safety margin even
in node-negative necks. For these cases, we have performed
submandibular neck dissections (SMNDs). SMND is a
superselective neck dissection in only level I necks and is
a minimally invasive procedure. We use a transcervical and
pull-through approach for resection of the primary tumor
and submandibular lymph nodes en bloc.
For clinically node-positive necks, a radical neck dissec-
tion (RND) or modiﬁed radical neck dissection (MRND)
remains the standard surgical treatment [6]. However,
selective neck dissection in such cases has been reexamined
with increasing understanding of anatomic structures and
lymphatic drainage [4, 7]. Several studies have demonstrated
the eﬃcacy of SOHND in the clinically N1 neck, with
outcomes similar to those of RND and MRND [8, 9]. How-
ever, postoperative morbidity, such as shoulder dysfunction,
has been reported even with SOHND, leading surgeons
to consider less-invasive procedures. At our institution,
improvements in imaging have enabled the accurate preop-
erativediagnosisofmetastaticnodes[10].Therefore,wehave
performed SMNDs as the initial operation for therapeutic
neckdissectionsinclinicallyN1neckswithmetastasistolevel
I,followedbycarefulobservationforregionalrecurrenceand
immediate salvage treatment if metastasis is detected.
This study aimed to evaluate the eﬃcacy of SMND in
elective and therapeutic situations involving OSCC.
2. Patientsand Methods
We reviewed the medical records of all patients with
untreated OSCC who underwent deﬁnitive surgery at the
Oral and Maxillofacial Surgery, Kyushu University Hospital,
between1989and2009andperformedaretrospectivecohort
study. Patients were followed up at least 5 years after surgery.
A total of 384 patients were initially identiﬁed. Five patients
droppedoutwithin5yearsandwereexcludedfromthestudy
(follow-up rate: 98.7%). Patients with distant metastasis
at the initial visit were excluded. The patients who had
positive surgical margins at the primary tumor site were
excluded from the study because they received extensive
salvage surgery or adjuvant chemoradiotherapy. Of these,
229 had clinically deﬁned N0 necks, and 68 had clinically
deﬁned N1 necks with metastasis to level I.
All patients underwent radical excision of the primary
tumor. Our initial therapeutic approach to cervical metas-
tasis is as follows. (1) Elective neck dissection is not, in
principle, performed in clinically deﬁned N0 necks. (2)
SMND is performed in N0 necks with a transcervical and
pull-through approach for resection of primary tumor and
reconstructive surgery. (3) SMND is performed in N1 necks
with metastasis only to level I. (4) RND is performed in
N1 necks with metastasis to level II or beyond and in N2
necks. Previously, we had performed MRND in N0 necks
needing reconstruction (2 above) and RND or MRND in
all of the clinically node-positive necks. Most patients who
had advanced disease (stage III or IV) received neoadjuvant
chemoradiotherapy.
We analyzed the type of neck dissection, use of neoad-
juvant or adjuvant therapy, and histopathological factors
(e.g., tumor cell diﬀerentiation, mode of invasion, and
extracapsular spread). The disease was staged according
to the International Union Against Cancer (UICC) TNM
classiﬁcation [11]. Classiﬁcation of neck lymph nodes was
done according to the neck dissection classiﬁcation by
the American Academy of Otolaryngology Head and Neck
Surgery (AA-OHN) [1]. Tumor cell diﬀerentiation was
determined using the World Health Organization (WHO)
classiﬁcation scheme [12], and the mode of invasion was
determined using the grading system described by Anneroth
et al. [13]. Tumor depth in tongue carcinoma was calculated
by measuring from the presumed normal mucosal surface
to the deepest point of the tumor using magnetic resonance
imaging (MRI) and ultrasonography (US). All lymph nodes
resected in the surgery were pathologically analyzed. The
main outcomes were 5-year regional control and 5-year
disease-speciﬁc survival (DSS) according to the type of neck
dissection, based on the Kaplan-Meier method and log-rank
tests.A Cox’s proportional hazardmodel withunivariate and
multivariate analysis was used to determine variables related
to regional control and the DSS. A chi-square test or Fisher’s
exact test was used to compare the characteristics of each
cohort.StatisticalsigniﬁcancewasdeﬁnedasaP value<0.05.
The protocol for the research project was approved by a
suitably constituted Ethics Committee of Kyushu University.
All patients gave informed consent to the individual treat-
ment.
3. Results
A total of 297 patients (172 men, 125 women) were included
in the analysis. The mean age was 64.3 years (range, 24–87
years). The median followup was 72 months (range, 12–210
months).
3.1. Clinically N0 Neck. Among 229 patients with clinically
node-negative necks, 110 underwent neck dissection at
the initial operation according to the protocol described
above, and 119 patients underwent resection of the primary
tumor only. The patient characteristics are shown in Table 1.
Regional recurrence was present in 16 (14.5%) patients who
underwent neck dissection and 21 (17.6%) who did not
undergoneckdissection.The5-yearregionalcontrolratewas
85.2% in patients who had neck dissections and 82.9% in
those who did not (P = 0.68), and the 5-year DSS rate was
88.0% and 85.5%, respectively, (P = 0.78).
Of 110 patients who underwent neck dissection, 77
(70%) underwent SMND and 33 (30%) underwent MRND.
The patient characteristics are shown in Table 2.P o s i t i v eJournal of Oncology 3
Table 1: Characteristics of patients (elective neck dissection versus observation).
Elective neck dissection Observation P value
Primary tumor site
0.565
Tongue 41 (37.3%) 43 (36.1%)
Lower gum 44 (40.0%) 38 (31.9%)
Upper gum 10 (9.1%) 13 (10.9%)
Buccal mucosa 9 (8.2%) 14 (11.8%)
Oral ﬂoor 3 (2.7%) 8 (6.7%)
Others 3 (2.7%) 3 (2.5%)
Clinical primary tumor stage
cT1/2 78 (70.9%) 86 (72.3%) 0.467
cT3/4 32 (29.1%) 33 (27.7%)
Tumor diﬀerentiation
Poorly diﬀerentiated 7 (6.4%) 6 (5.0%)
0.788 Moderately diﬀerentiated 32 (29.1%) 39 (32.8%)
Well diﬀerentiated 71 (64.5%) 74 (62.2%)
Neoadjuvant chemoradiotherapy 38 (34.5%) 42 (35.3%) 0.508
Total 110 119
nodes were identiﬁed histopathologically on the excised
specimen in 5 (6.5%) of the 77 patients who underwent
SMND and 4 (12.1%) of the 33 who underwent MRND.
Among the 4 patients with positive nodes who underwent
MRND, 2 had metastases at level I, one at level IIA,
and one had multiple metastases at level I and IIA. No
patient had evidence of “skip metastasis” to level III or
IV or metastasis to level IIB or V. Occult metastases were
present in 9 (8.2%) of all 110 patients, and the remain-
ing 101 (91.8%) patients had histopathologically node-
negative disease. Regional recurrences were documented in
11 (14.3%) patients who underwent SMND and 5 (15.1%)
who underwent MRND, resulting in 5-year regional control
ratesof85.2%and83.3%,respectively,(P = 0.89)(Figure 1).
Most of the nodal metastases in patients who underwent
SMND were in the ipsilateral neck (8 at level IIA and 1 with
multiple metastases at level IIA and III), while 2 were present
at level I of the contralateral neck. Most of the patients with
nodal metastases experienced regional recurrence within
several months to a year. Only 1 patient who underwent
MRND had regional recurrence in the ipsilateral neck (i.e.,
intraglandular parotid node, outside of the neck dissection),
while 4 had recurrence in the contralateral neck: 2 at level
I, 1 at level IIA, and 1 at level IIA and III. The 5-year
DSS rate was 86.5% with SMND and 87.0% with MRND
(P = 0.94) (Figure 2). On multivariate analysis (Table 3),
regional control was negatively associated with pathological
nodal stage (node-positive) and extracapsular spread and
positively associated with administration of neoadjuvant
chemoradiotherapy. DSS was negatively associated with
clinical tumor stage, pathological nodal stage, extracapsu-
lar spread, and neoadjuvant chemoradiotherapy. Regional
control and survival were not signiﬁcantly associated with
type of neck dissection on either univariate or multivariate
analysis.
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Figure 1: The Kaplan-Meier 5-year regional control rates by type
of neck dissection (SMND versus MRND) in clinically N0 necks.
SMND: selective submandibular neck dissection; MRND: modiﬁed
radical neck dissection.
3.2. Clinically N1 Neck. Among 68 patients who had clin-
ically N1 necks with metastasis to level I, 32 underwent
SMND and 36 underwent RND. The patient characteristics
are shown in Table 2. Of the 32 patients who underwent
SMND, 5 (including the cases of complete response on pre-
operativechemoradiotherapy)hadhistopathologicallynode-
negative necks, and the other 27 had histopathologically
positive necks, including 3 patients with multiple metastases
at level I. Of the 36 patients who underwent RND, 6 had
histopathologically N0 necks, 25 had pN1 (at level I) necks,
and 5 had pN2b neck. Among these 5 patients, 2 had
multiple nodal metastases at level I, 2 at level I and sublevel
IIA, and one at level I, IIA, III. Eight (11.8%) of all 684 Journal of Oncology
Table 2: Characteristics of patients who underwent neck dissection (clinically N0 neck/clinically N1 neck).
Type of neck dissection Clinically N0 neck (110) Clinically N1 neck (68)
SMND (77) MRND (33) P value SMND (32) RND (36) P value
Primary tumor site
0.825
Tongue 28 (36.4%) 13 (39.4%) 0.923 14 (43.8%) 13 (36.1%)
Lower gum 31 (40.3%) 13 (39.4%) 11 (34.4%) 14 (38.9%)
Upper gum 7 (9.1%) 3 (9.1%) 3 (9.4%) 4 (11.1%)
Buccal mucosa 6 (7.8%) 3 (9.1%) 1 (3.1%) 3 (8.3%)
Oral ﬂoor 2 (2.6%) 1 (3.0%) 3 (9.4%) 2 (5.6%)
Others 3 (3.9%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Clinical tumor stage
cT1/2 55 (71.4%) 23 (69.7%)
0.513
10 (31.3%) 9 (25.0%) 0.381
cT3/4 22 (28.6%) 10 (30.3%) 22 (68.7%) 27 (75.0%)
Tumor diﬀerentiation
Poorly diﬀerentiated 5 (6.5%) 2 (6.1%)
0.982
2 (6.3%) 2 (5.6%)
0.991 Moderately diﬀerentiated 22 (28.6%) 10 (30.3%) 9 (28.1%) 10 (27.8%)
Well diﬀerentiated 50 (64.9%) 21 (63.6%) 21 (65.6%) 24 (66.7%)
Mode of invasion
Grade 1–3 58 (75.3%) 23 (69.7%)
0.348
22 (68.8%) 23 (63.9%) 0.435
Grade 4 19 (24.7%) 10 (30.3%) 10 (31.2%) 13 (36.1%)
Neoadjuvant chemoradiotherapy 26 (33.8%) 12 (36.4%) 0.479 19 (59.4%) 19 (52.8%) 0.325
Pathological nodal stage
0.603
pN0 72 (93.5%) 29 (87.9%) 5 (15.6%) 6 (16.7%)
0.828 pN1 4 (5.2%) 3 (9.1%) 24 (75.0%) 25 (69.4%)
pN2b 1 (1.3%) 1 (3.0%) 3 (9.4%) 5 (13.9%)
Extracapsular spread 1 (1.3%) 2 (6.1%) 0.214 3 (9.4%) 4 (11.1%) 0.567
Adjuvant chemoradiotherapy 5 (6.5%) 4 (12.1%) 0.264 2 (6.3%) 4 (11.1%) 0.395
SMND: selective submandibular neck dissection; RND: radical neck dissection; MRND: modiﬁed radical neck dissection.
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Figure 2: The Kaplan-Meier 5-year disease-speciﬁc survival rates
by type of neck dissection (SMND versus MRND) in clinically N0
necks. SMND: selective submandibular neck dissection; MRND:
modiﬁed radical neck dissection.
patients had occult nodal metastases, and no patients had
skip metastasis to level III or IV or metastases to level IIB
or IV. Six (18.8%) patients who underwent SMND and
6 (16.7%) who underwent RND had regional recurrence,
leading to 5-year regional control rates of 81.3% and 83.0%,
respectively, (P = 0.72) (Figure 3). Of the 6 patients who
underwent SMND followed by regional recurrences, 4 had
recurrences in the ipsilateral neck: 3 at level IIA and 1 at
level IIA and III. The other 2 had recurrences at level I in
the contralateral neck. Most of them experienced regional
recurrences within 1 year. Of the 6 patients who underwent
RND followed by regional recurrences, 1 had a recurrence
in the parapharyngeal space of the ipsilateral neck, while
5 had recurrences in the contralateral neck: 2 at level I, 2
at level IIA, and 1 at level IIA, III. The 5-year DSS rate
was 81.3% after SMND and 80.0% after RND, respectively,
(P = 0.94) (Figure 4). On multivariate analysis, as in N0
neck, regional control and DDS were negatively associated
with pathological nodal stage (pN2) and extracapsular
spread and positively associated with administration of
neoadjuvantchemoradiotherapy.Thetypeofneckdissection
did not signiﬁcantly correlate with regional recurrence and
DDS on either univariate or multivariate analysis (Table 4).
Postoperative limited shoulder mobility was present in 11
(30.6%) of the 36 patients who underwent RND.
4. Discussion
Indications for elective neck dissection and its appropriate
extent in patients with OSCC remain controversial. ElectiveJournal of Oncology 5
Table 3: Cox’s proportional hazard model with univariate and multivariate analysis in clinically N0 necks.
Regional control Disease-speciﬁc survival
Univariate Multivariate Univariate Multivariate
Hazard ratio
(95% CI) P value Hazard ratio
(95% CI) P value Hazard ratio
(95% CI) P value Hazard ratio
(95% CI) P value
Type of neck dissection
MRND/SMND
1.061
(0.381–2.935) 0.913 0.986
(0.337–2.886) 0.980
Clinical tumor stage T3,
4/T1, 2
1.896
(0.742–2.885) 0.204 3.048
(1.105–8.043) 0.031 14.949
(8.643–21.352) 0.002
Primary tumor site
Tongue
1.113
(0.412–2.080) 0.857 1.219
(0.539–3.052) 0.794
Tumor depth (Tongue)
4mm
1.687
(0.659–4.260) 0.465 2.386
(0.935–4.777) 0.061
Poorly or Moderately
diﬀerentiated
1.061
(0.403–2.446) 0.913 1.490
(0.530–4.187) 0.449
Mode of invasion
Grade 4
2.074
(0.815–4.243) 0.148 1.975
(0.871–4.130) 0.350
Neoadjuvant
chemoradiotherapy
0.277
(0.107–0.825) 0.045 0.136
(0.050–0.469) 0.049 0.269
(0.076–0.953) 0.042 0.412
(0.150–0.924) 0.032
Pathological nodal stage
pN(+)
5.101
(2.470–10.172) 0.003 3.542
(1.447–7.122) 0.027 4.081
(1.299–12.816) 0.016 6.541
(2.463–9.257) 0.014
Extracapsular spread 5.095
(1.383–18.461) 0.031 31.333
(13.443–75.119) 0.005 5.487
(2.238–14.315) 0.025 15.915
(11.440–27.967) 0.024
Adjuvant
chemoradiotherapy
2.589
(0.643–8.849) 0.137 2.806
(0.792–9.942) 0.110
SMND: selective submandibular neck dissection; MRND: modiﬁed radical neck dissection; CI: conﬁdence interval.
Table 4: Cox’s proportional hazard model with univariate and multivariate analysis in clinically N1 necks.
Regional control Disease speciﬁc survival
Univariate Multivariate Univariate Multivariate
Hazard ratio
(95% CI) P value Hazard ratio
(95% CI) P value Hazard ratio
(95% CI) P value Hazard ratio
(95% CI) P value
Type of neck dissection
RND/SMND
0.889
(0.289–2.412) 0.838 0.897
(0.224–2.263) 0.962 0.989
(0.346–3.086) 0.948 0.898
(0.209–2.225) 0.796
Clinical tumor stage T3,
4/T1, 2
2.857
(0.794–5.941) 0.086 3.112
(0.990–10.434) 0.040 2.465
(1.107–5.261) 0.071
Primary tumor site
Tongue
1.129
(0.443–2.676) 0.877 1.024
(0.497–2.311) 0.798
Tumor depth (tongue)
4mm
1.857
(0.665–3.838) 0.101 1.414
(0.736–4.109) 0.385
Poorly or moderately
diﬀerentiated
2.238
(0.733–4.496) 0.163 3.212
(0.876–7.769) 0.073
Mode of invasion
Grade 4
3.250
(1.805–7.727) 0.041 2.966
(0.849–7.330) 0.760 3.814
(1.018–9.012) 0.036 3.145
(1.883–7.516) 0.240
Neoadjuvant
chemoradiotherapy
0.263
(0.092–0.706) 0.045 0.195
(0.087–0.451) 0.013 0.312
(0.152–0.942) 0.039 0.232
(0.090–0.596) 0.018
Pathological nodal stage
pN2
3.750
(1.825–7.586) 0.031 6.869
(2.681–14.011) 0.022 5.847
(1.888–10.719) 0.005 6.989
(2.428–12.111) 0.004
Extracapsular spread 6.224
(2.484–12..234) 0.002 11.342
(5.880–20.419) <0.001 9.868
(4.510–18.225) <0.001 12.767
(6.926–19.446) <0.001
Adjuvant
chemoradiotherapy
1.743
(0.454–4.379) 0.473 2.637
(0.720–9.499) 0.129
SMND: selective submandibular neck dissection; RND: radical neck dissection; CI: conﬁdence interval.6 Journal of Oncology
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Figure 3: The Kaplan-Meier 5-year regional control rates by type
of neck dissection (SMND versus RND) in clinically N1 necks.
SMND:selectivesubmandibularneckdissection;RND:radicalneck
dissection.
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Figure 4:TheKaplan-Meier5-yeardisease-speciﬁcsurvivalratesby
type of neck dissection (SMND versus RND) in clinically N1 necks.
SMND:selectivesubmandibularneckdissection;RND:radicalneck
dissection.
neck dissection has become more widely used due to the
possibility of occult metastases to cervical lymph nodes
[2]. Weiss et al. reported that elective treatment of the
neck is warranted if the probability of occult metastases is
determined to be greater than 20% using decision analysis
[14]. The reported probability of occult metastasis has
ranged widely from 8 to 48.2%, based on a variety of
methods such as routine hematoxylin-eosin staining and
immunohistochemical or molecular analysis [2, 15, 16].
Although several predictors of occult metastases have been
assessed (e.g., tumor depth, tumor cell diﬀerentiation, mode
of invasion, and expression of molecular markers) [17–19],
micrometastases remain diﬃcult to detect preoperatively.
Thus, elective neck dissection has been performed without
an established method for assessing the probability of occult
metastases. Furthermore, several studies have demonstrated
that regional control and overall survival are similar in
elective neck dissection and observation, as well as in salvage
treatment for regional recurrence [20–22].
Based on these various research ﬁndings and practices,
one must carefully consider and discuss with the patient
whether or not to perform elective neck dissection in clin-
ically N0 necks, because such an approach could constitute
overtreatment and unnecessarily compromise the patient’s
qualityoflife.Toassistinthesedecisions,wehaveusedpower
Doppler US and enhanced computed tomography (CT) to
examine patients for metastatic lymph nodes. These tests
have proven diagnostically sensitive and speciﬁc [10]. Addi-
tionally, the incidence of occult metastases was 12.1% in our
series (Table 2), even in patients treated with elective radical
neck dissection. This rate is below the suggested probability
of occult metastases (20%) described by Weiss et al. [14]. For
this reason, we do not perform elective neck dissections at
present. We have performed salvage neck dissection when
metastatic nodes are detected. Therefore, careful followup,
including frequent imaging tests with US as the primary
imaging modality, is needed to detect regional recurrence
immediately. We recommend US because it involves less
radiation exposure than CT imaging. As mentioned in
Section 2, we have performed elective neck dissection only in
cases of a transcervical approach with reconstructive surgery.
Accordingly, although we could not assess the signiﬁcance of
elective neck dissection in all patients, regardless of the need
for reconstructive surgery, we found that regional control
and DSS were equivalent in patients who underwent neck
dissection and those who underwent tumor resection with-
out neck dissection, followed by observation. Consequently,
elective neck dissection does not contribute to improved
outcome, and our “watchful” treatment strategy for the
clinically N0 neck seems justiﬁed.
Several studies, including multi-institutional prospec-
tive randomized studies, have demonstrated that regional
control and survival in the clinically negative neck were
similar in patients treated with SOHND and MRND.
Thus, SOHND has gradually gained acceptance in elective
situations [3]. However, some authors have recommended
extended SOHND, including level IV, due to the high
incidence of skip metastasis to levels III and IV [2, 23]a n d
lymphatic drainage to level II–IV from tongue carcinoma
[7]. In addition, some authors have argued that sublevel
IIB may be preserved in elective neck dissections, because
OSCC rarely metastasizes to this sublevel [24]. As with
extended SOHND, ordinary SOHND including sublevel IIB
may cause dysfunction of the accessory nerve, as well as
phrenic neuropathy, chyle ﬁstula, and cosmetic disturbance
[2]. In this way, even “selective” elective neck dissection
may be overly invasive for patients with clinically negative
necks. We had performed MRND as elective neck dissection
along with resection of primary tumors in the past. At
present,however,weperformSMND,whichismoreselective
and less invasive than SOHND, based on the conclusion
that elective neck dissection is unnecessary. We found that
regional control and DDS were equivalent after SMND and
MRND regardless of the primary site or histopathologicalJournal of Oncology 7
malignancy grade; in addition, no patients in our series
had evidence of skip metastasis to level III or IV. Most
regional recurrence in patients with SMND was detected
at level IIA in the ipsilateral neck within 1 year. Although
these patients may have had occult metastases outside the
SMND, 7 of 11 patients with regional recurrence underwent
successful salvage surgery. In addition, 101 of 110 patients
withclinicallyN0neckswereconﬁrmedonhistopathological
examination to be node negative; therefore, the diagnostic
accuracy of imaging tests for detecting metastatic nodes
was considered excellent. Thus, we do believe that SMND
is acceptable as an elective neck dissection to accompany
primary tumor resection.
Therapeutic selective neck dissection in the clinically
positive neck remains more controversial. Several studies
havereportedthatregionalcontrolwiththerapeuticSOHND
in clinically N1 or N2 necks was not very diﬀerent from that
withMRND[8,9].Inamulti-institutionalprospectivestudy,
the authors recommended SOHND for all patients with
clinically N1 necks [25]. On the other hand, another study
demonstrated that RND should be performed in clinically
positive necks because of the risk of skip metastasis to levels
IIIandIVandofincompletedissectionwithSOHND[6,23].
However,moreextensiveneckdissectioncausesmoreserious
morbidity, as Krause reported that 31% of patients with
RND had severe shoulder dysfunction (72% of patients had
s o m eg r a d eo fd y s f u n c t i o n )[ 26]. We assessed the eﬃcacy of
SMND in clinically N0 necks, as noted earlier, and had good
results following salvage treatment for patients with regional
recurrence. Based on these ﬁndings, in recent years we have
performed SMND even as a therapeutic neck dissection in
clinically N1 necks with metastasis only to level I. In the
current series, regional control and DDS in this situation
were similar for both SMND and RND, and the outcomes
were considered acceptable. The primary tumor site and
histopathological malignancy grade did not signiﬁcantly
correlate with outcome on multivariate analysis. This further
indicated that SMND was appropriate for all patients with
clinically N1 necks with metastasis to level I. Most regional
recurrence in patients who underwent SMND, as well as
in patients with N0 necks, was detected at sublevel IIA in
the ipsilateral neck early in followup. Among 6 patients
who had regional recurrence, 4 underwent successful salvage
treatment. The fact that all the regional recurrences were
detected in dissection levels of SOHND suggests that SMND
is inferior to SOHND with regard to completeness of
operation.Nevertheless,wewereabletoavoidoverlyinvasive
surgery and prevent postoperative shoulder syndrome, the
main residual disability that signiﬁcantly reduces quality of
life in patients without regional recurrences. Hence, SMND
should be planned only if the patients can be followed up
byfrequentandstrictpostoperativemanagement.Webelieve
that therapeutic SMND can be applied to carefully chosen
patientswithOSCC,giventhelowincidenceofpostoperative
functional or cosmetic disorders and excellent outcomes.
In addition, 60 of 68 patients with clinically N1 necks
were histopathologically conﬁrmed to have N0 (including
complete responses to preoperative therapy) or N1 necks.
Our strategy for the application of selective neck dissection
may also be supported by accurate preoperative diagnosis
and immediate salvage treatment on regional recurrence.
5. Conclusion
In summary, this is the ﬁrst paper evaluating the validity
of new superselective neck dissection. SMND is an eﬀective
treatment for OSCC with N0 necks or N1 necks with
metastasis to level I, when careful followup is provided to
detect regional recurrence immediately. Cervical metastasis
is the most crucial prognostic factor in the treatment of
OSCC.
Therefore, further prospective randomized studies
should be planned based on this retrospective study.
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